

Kallikrein 7/KLK7 Protein, Cynomolgus, Recombinant (His)

General Information

| | |
|-----------------------|---|
| Synonyms: | Serine protease 6;KLK7;Kallikrein-7;hK7;hSCCE;SCCE;PRSS6 |
| Protein Construction: | Ile30-Arg253 |
| Species: | Cynomolgus |
| Expression Host: | HEK293 Cells |
| Accession: | XP_045235576.1 |
| Molecular Weight: | 25.93 kDa (Predicted); 27-35 kDa (Reducing condition, due to glycosylation) |

QC Testing

| | |
|----------------------|---|
| Biological Activity: | Immobilized Cynomolgus Kallikrein 7, His Tag at 0.5 µg/ml (100 µl/well) on the plate. Dose response curve for Anti-Kallikrein 7 Antibody, hFc Tag with the EC50 of 3.6 ng/ml determined by ELISA (QC Test). |
| Purity: | > 95% as determined by Bis-Tris PAGE |
| Endotoxin: | < 0.1 EU/µg of the protein as determined by the LAL method. |
| Formulation: | Lyophilized from 0.22 µm filtered solution in 20 mM Hepes, 150 mM NaCl, 8% trehalose, 0.05% Brij-35, 5 mM Benzamidine (pH 7.5). |

Preparation and Storage

Reconstitution:

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 µg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

Kallikrein 7 (KLK7) is a secreted serine protease with chymotrypsic protease activity. Abnormally high expression of KLK7 is closely related to the occurrence and development of various types of cancer. Therefore, KLK7 has been identified as a potential target for cancer drug development design in recent years. KLK7 mediates various biological and pathological processes in tumorigenesis, including cell proliferation, migration, invasion,

A DRUG SCREENING EXPERT

angiogenesis, and cell metabolism, by hydrolyzing a series of substrates such as membrane proteins, extracellular matrix proteins, and cytokines.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481